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2034ABSTRACT
Background. To investigate the expression of RANTES (regulated upon activation,
normal T-celleexpressed and esecreted) and monocyte chemoattractant proteine1 (MCP-
1) in renal allografts with chronic renal allograft dysfunction (CRAD), and explore its
relationship with interstitial ﬁbrosis and tubular atrophy (IF/TA).
Methods. An immunohistochemical assay and computer-assisted, genuine colored image
analysis system were used to detect the expression of RANTES and MCP-1 in renal
allografts with CRAD. The relationship among the expression level of MCP-1, RANTES,
and the grade of inﬂammatory cell inﬁltration, interstitial ﬁbrosis, and tubular atrophy in
renal allografts were analyzed. Ten specimens of healthy renal tissue were used as controls.
Results. Compared to the normal tissues, the expressions of RANTES and MCP-1 were
signiﬁcantly higher in the renal tissues with CRAD (P < .001), and the expressions tended
to increase along with the pathological grade of IF/TA. The expression of RANTES and
MCP-1 were positively correlated with the pathological grades of IF/TA (r ¼ 0.940 and
0.954 respectively, P < .001 for both).
Conclusion. In renal allograft tissue with CRAD, the up-regulated expressions of
RANTES and MCP-1 may be related to the progression of chronic renal allograft
dysfunction and allograft ﬁbrosis.This work was supported by Natural Science Foundation of
Guangxi (No: 2014GXNSFAA118179), Self-funded Research Pro-
jects of Guangxi Health Department (No. Z2014533), and Science
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E-mail: yanqiang1967@sohu.comCURRENTLY, kidney transplantation is the optimaltreatment for patients with end-stage renal disease
(ESRD) and is widely regarded as the gold standard in renal
replacement therapy. The short-term survival rate of renal
transplantation has increased signiﬁcantly, due to the use of
novel immunosuppressants and the improvements in surgi-
cal techniques and postoperative care. In the past 20 years,
the 1-year allograft survival rate has increased from 50% to
almost 90% after kidney transplantation. However, the
long-term survival rate is still lower in the current decade, as
the long-term renal allografts survival is still 68% in living
donor and 51% in cadaveric donor [1] transplants.
The main factors inﬂuencing renal allograft survival are
cardiovascular disease and chronic renal allograft dysfunction
(CRAD). There is less reported about RANTES (regulated
upon activation, normal T-celleexpressed and esecreted) and
monocyte chemoattractant proteine1 (MCP-1) in patients
with CRAD. Therefore, in this study, we focused mainly on
detecting the expression of RANTES, MCP-1, and collagen6
.org/10.1016/j.transproceed.2016.05.007IV in the tissue of renal allografts, and analyzed their
relationship with interstitial ﬁbrosis and tubular atrophy
(IF/TA), for exploring the role of RANTES and MCP-1 in
the development of chronic renal allograft dysfunction.
METHODS
Clinical Data
Renal biopsy samples were collected from renal transplant patients
with elevated serum creatinine levels and proteinuria from Januaryª 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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RANTES AND MCP-1 IN RENAL ALLOGRAFT DYSFUNCTION 20352008 to January 2013 in Guilin No. 181 Hospital of Southern
Medical University of China. Among the 40 patients with clinical
diagnoses of chronic renal allograft dysfunction (CRAD), 23 were
male (aged 44  11 years) and 17 were female (aged 47  5 years).
The duration between sample collection and kidney transplantation
was 0.5e12 years. The patients’ mean level of serum creatinine was
302  206 mmol/L. The triple immunosuppressant protocols were
tacrolimus þ mycophenolate mofetil þ prednisone in 15 patients,
and cyclosporine þ mycophenolate mofetil þ prednisone in the
remaining 25 patients. Before renal biopsy, serum drug concentra-
tion test and color Doppler ultrasound detection of renal allografts
were performed to exclude acute rejection, obstruction/reﬂux of
bladder-ureter, nephrotoxicity of immunosuppressant, thrombosis
or embolism in renal arteries or veins, and other diseases [2]. Ac-
cording to the Banff 2013 criteria [3] pathological classiﬁcation
criteria for renal allografts, the patients were diagnosed with
CRAD. The donor and recipient were matched in regard to ABO
blood type, and two or more human leukocyte antigens (HLA) were
matched. The results of lymphocytotoxicity test were less than 10%,
and the results of panel reaction antibody (PRA) were negative.
The renal samples of 10 control cases were collected from routine
donor kidney biopsy samples before transplantation, the histologi-
cal manifestation of which was normal. Informed consent was ob-
tained from all patients who were involved in the study. Our study
was performed under the supervision of Institutional Review Board
of Southern Medical University, and abided by the principles of the
World Medical Association Declaration of Helsinki.
Histological Examination
The parafﬁn-embedded kidney sections were sliced into 3-mm-thick
tissue sections, which were deparaﬁnized through xylene and hy-
drated through graded ethanol (100%, 96%, 90%, and 70%) and
distilled water. Standard histological procedures were used to stain
the sections, including hematoxylin and eosin stain, Masson tri-
chrome, periodic-acid Schiff (PAS) staining, and periodic acid-silver
methenamine (PASM) staining. Hematoxylin and eosin staining
was used to assess the class of interstitial cellular inﬁltration and
tubular atrophy, Masson and PASM were used to evaluate the
interstitial ﬁbrosis and basement membrane disorder, and PAS
reaction was used to evaluate the arterio- and glomerulosclerosis.
Pathological Diagnosis
According to the Banff 2013 [3] pathological classiﬁcation criteria
for renal allografts, the degree of interstitial ﬁbrosis and tubular
atrophy was deﬁned as: IF/TA-I, mild interstitial ﬁbrosis and
tubular atrophy (<25% of cortical area); IF/TA-II, moderate
interstitial ﬁbrosis and tubular atrophy (26%e50% of cortical area);
and IF/TA-III, severe interstitial ﬁbrosis and tubular atrophy/loss
(>51 of cortical area).
Immunohistochemistry Examination
Immunohistochemistry with Envision was used to detect the
expression of RANTES, MCP-1, and C4d in the renal allograft
tissue. Parafﬁn sections with 3-mm thickness underwent routine
baking and were dewaxed step by step. A 3% hydrogen dioxide
solution was adopted to clear endogenous hydrogen peroxidase.
Before immunohistochemial staining, the antigens were micro-
waved for 15 minutes. Then the ﬁrst antibody (RANTES, rabbit
anti-human monoclonal antibody, Wuhan Boshide Company
product, No. BA-1383, 1:200 diluted; MCP-1, rabbit anti-human
monoclonal antibody, Wuhan Boster Biological Technologyproduct, No. BA-1254, 1:200 diluted; C4d, rabbit anti-human
polyclonal antibody, working solution Santa Cruz product, No.
ZA-0415) was added and incubated over night at 4C. After
washing with phosphate-buffered saline solution (PBS), rabbit anti-
mouse antibody (Fuzhou Maixin Company) was added, and the
sections were incubated for 30 minutes at 37C. PBS washing was
followed by DAB coloration and then hematoxylin counterstaining.
At the same time, immunohistochemisty tests for IgA, IgG, IgM,
Clq, C4c, and C3 were also performed in the same way. Immuno-
histochemical staining of each group was compared with the control
group, with PBS as a substitute for the ﬁrst antibody.
Positive results were deﬁned as pale yellow, brownish yellow, and
yellowish-brown particles appeared in tubular epithelial cell and
interstitial cell cytoplasm.
Image Semi-quantitative Analysis
Semi-quantitative analysis was performed by means of the Leica
DMR-XþQ550 renal color patho-image analysis system. Ten
discontinuous tubulointerstitial ﬁelds (400) per kidney were
randomly selected in different regions including the renal cortex,
cortex-medulla juncture, and medullary interstitium (not including
glomeruli and veins and arteries). More than 60 tubules were
observed in each part. Image-Pro Plus (IPP) was used to calculate
the average optical density (the ratio of the positive to the total area
excluding the area of tubular lumens). The relative expression of
each kind of molecules in kidney tubulo-interstitium was repre-
sented by the ratios.
Statistic Analysis
All experimental results were expressed as mean  standard devi-
ation (SD). SPSS 13.0 statistical software was performed to analyze
the experiment data. Measurement data was analyzed by single
factor analysis. The correlation between two variables was per-
formed with Pearson linear correlation. Statistical signiﬁcance was
set at the level of P < .05.RESULTS
Histological Examination
The main histological disorders of renal allograft tissue with
hematoxylin and eosin staining were expressed as follows:
the glomerular mesangial matrix became broader, and
diffuse inﬂammatory cells including lymphocytes and
monocytes were found in the renal interstitium. Under
Masson and PASM staining, there were increased mesangial
matrix and extracelluar matrix, thickening of glomerular
basement membranes, and false double track sign. There
were focal segmental glomerulosclerosis, interstitial ﬁbrosis,
and tubular atrophy accompanied by inﬁltration of inﬂam-
matory cells including monocytes and lymphocytes, and
thickening of Bowman’s capsule.
None of the manifestations of histological examination
coincided with presentation of nephrotoxicity of immuno-
suppressant, acute rejection, chronic glomerulonephritis, or
obstructive uropathy/reﬂux nephropathy.
RANTES Expression
There was either no or only rare expression of RANTES in
the normal renal tissue. However, in the renal allograft
Table 1. RANTES and Monocyte Chemoattractant Proteine1
(MCP-1) Expression in Renal Allografts of Patients With Chronic
Renal Allograft Dysfunction and Various Degrees of Interstitial
Fibrosis and Tubular Atrophy
Group n RANTES (%) MCP-1 (%) Collagen IV (%)
Normal
controls
10 1.83  0.77 4.05  1.33 10.14  3.39
IF/TA-I
group
17 18.53  4.93* 29.20  5.89* 37.11  6.60*
IF/TA-II
group
14 30.98  8.68*,† 48.36  9.17*,† 52.91  6.75*,†
IF/TA-III
group
9 52.60  4.77*,†,‡ 67.78  6.82†,‡ 67.18  4.75*,†,‡
Data are mean  standard deviation.
Abbreviation: IF/TA, interstitial ﬁbrosis and tubular atrophy.
*P < .001 vs control group.
†P < .001 vs IF/TA-I group.
‡P < .001 vs IF/TA-II group.
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expressed in the tubular epithelia and mesangial area, along
with signiﬁcant inﬂammatory cell inﬁltration in the renal
interstitium. The stronger expression of RANTES inFig 1. Expressions of RANTES in kidney allograft tissues with chr
Group IF/TA-I. (C) Group IF/TA-II. (D) Group IF/TA-III (EnVision assayallograft tissue was accompanied by more monocyte and
lymphocyte inﬁltration and by severe tubulointerstitial dis-
orders. The expression of RANTES increased along with
the increase in IF/TA classiﬁcation (r ¼ 0.940, P < .001)
(Table 1 and Fig 1).
MCP-1 Expression
Weak MCP-1 expression was observed in renal tissue of
controls. However, in the renal allograft tissue with CRAD,
MCP-1 expression was signiﬁcantly shown in the cytoplasm
of interstitial cells, mesangial area, and endothelial side
of glomerular capillary loops. The expression of MCP-1
increased along with the increase in IF/TA pathological
grade (r ¼ 0.954, P < .001) (Table 1 and Fig 2).
DISCUSSION
Renal transplantation results in improved quality of life
and survival time of patients with end-stage kidney dis-
ease. However, the long-term renal allograft survival rate
remains extremely low. Inﬂammatory cell inﬁltration plays
an important role in chronic inﬂammation and interstitialonic renal allograft dysfunction (CRAD). (A) Normal controls. (B)
, original magniﬁcation 400).
Fig 2. Expressions of monocyte chemoattractant proteine1 (MCP-1) in kidney allograft tissues with CRAD. (A) Normal controls. (B)
Group IF/TA-I. (C) Group IF/TA-II. (D) Group IF/TA-III (EnVision assay, original magniﬁcation 400).
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initial culprit in the development of renal ﬁbrosis [4]. In
the early stage of CRAD, the inﬁltration of monocytes is
the primary pathological manifestation. As is well known,
the inﬁltration, accumulation, and activation of inﬂam-
matory cells require chemokines to participate in the
pathogenesis. However, the mechanism has not been fully
explored, as there was lack of research on its pathological
mechanism in previous literature. In our present study, we
ﬁrst report that RANTES and MCP-1 are involved in the
pathogenesis of CRAD, and their high expression is
closely related to inﬂammatory cell inﬁltration, interstitial
ﬁbrosis, and tubular atrophy, which were induced by
CRAD.
Numerous research articles over the past decade have
provided compelling evidence to suggest that macrophages
could cause chronic progressive renal damage. Pilmore et al
[5] found that the degree of myoﬁbroblast proliferation
and macrophage inﬁltration in early biopsy specimens
predicted the subsequent development of CAN. There is
also evidence to suggest that the degree of macrophageinﬁltration positively correlated with the degree of renal
ﬁbrosis in an in vivo study of rats, and the degree of renal
ﬁbrosis was alleviated when knocking out the macrophage
gene or inhibiting the gene encoding the generation of
macrophages [6]. Liposome-clodronate can selectively
deplete macrophage inﬁltration from unilateral ureteral
obstruction (UUO), and can markedly suppress the pro-
gression of renal interstitial ﬁbrosis [7]. Monocytes are
recruited to the interstitium of renal allograft by local pro-
duction of chemokines and cytokines including RANTES
and MCP-1 [8,9]. RANTES and MCP-1 are two important
members of CC-chemokine family. They play important
roles in inﬂammatory cell inﬁltration, activation, and
development of ﬁbrosis in the transplanted kidney, and a
recently study has demonstrated that blockade of MCP-1
can have profound effects on islet allograft survival [10].
In addition, RANTES and MCP-1 not only contribute to the
accumulation and activation of lymphocytes and monocytes/
macrophages in the renal interstitium, but also are secreted
by those inﬂammatory cells; thus, a positive feedback loop
could be formed. This pathological process has been found
2038 YAN, JIANG, WANG ET ALto aggravate glomerular and tubulointerstitial damage as
well as inﬂammatory cells inﬂux and activation [11,12].
Transforming growth factoreb (TGF-b1) is an important
effect factor that is necessary for the synthesis and degra-
dation of extracellular matrix (ECM) [13]. Collagen IV is
the major component of collagens in the kidney, and it has
been demonstrated that the overexpression of ECM (espe-
cially collagen IV) is a signiﬁcant pathological event in the
development of renal ﬁbrosis [14]. It has been found in our
previous study in CRAD patients that collagen IV deposit in
the kidney interstitium could be an important process in the
renal allograft ﬁbrosis [15], and that macrophage not only
secretes several inﬂammatory cytokines that could induce
persistent injury of mesangial cells and tubular epithelial
cells, but also generates a large number of pro-ﬁbrogenic
factors, such as TGF-b1 and platelet-derived growth factor
(PDGF), resulting in overgeneration of extracellular matrix,
collagen IV, and renal ﬁbrosis [16]. Furthermore, in our
present study, it is suggested that the high expression of
RANTES and MCP-1 signiﬁcantly correlated with IF/TA
processes in the pathological mechanism of CRAD.
In a study of diabetic nephropathy contributing to inter-
stitial ﬁbrosis, it was shown that MCP-1 played an important
role in macrophage recruitment and migration, and that the
macrophages could secrete interleukin-1b that acts as a
growth factor in renal mesangial cells to increase the gen-
eration of TGF-b, PDGF, and collagen IV in diabetic ne-
phropathy, eventually leading to renal ﬁbrosis [17]. In a rat
model of nephrosis, Wastson et al [18] found that RANTES
and MCP-1 DNA vaccines can protect against chronic renal
disease by reducing the recruitment of T cells and macro-
phages. Evidently, upregulation of RANTES and MCP-1
may play a vital role in the pathological and molecular
mechanisms of progressive chronic renal allograft dysfunc-
tion. In our present study we also found that the expression
of RANTES and MCP-1 were much higher than in normal
renal tissue, and become stronger along with the increasing
IF/TA pathological grade. This is consistent with our pre-
vious study of CRAD in a rat model [19].
It was shown in our previous study that in vivo blockade
of chemokine receptors by Met-RANTES, an antagonist of
CCL5/RANTES chemokine receptors, could decrease early
inﬁltration and activation of monocytes in renal allograft
tissue, as well as markedly improve IF/TA, and thereby
prolong renal allograft survival time [20]. Other authors
have found that CCR1 antagonist BX 471 could markedly
reduce the mRNA expression of ﬁbrogenic cytokine plas-
minogen activator inhibitore1 (PAI-1) and TGF-b1, and
weaken collagen deposition in renal grafts; in addition, the
development and progression of chronic allograft dysfunc-
tion was signiﬁcantly inhibited by BX471 [21]. The results of
the above studies suggest that CC chemokine MCP-1,
RANTES, and their receptors play major roles in chronic
allograft damage.
Renal allograft ﬁbrosis is a complex pathophysiological
processes that is mediated by a number of inﬂammatory
cells, including macrophages and T cells. It requires anorchestrated series of molecular events including the
participation of TGF-b1, PDGF, PAI-1, and TIMP-1, and
also needs the participation of chemotatic proteins such as
RANTES and MCP-1. It is demonstrated in our study that
RANTES and MCP-1 play important roles in the initial
recruitment and activation of inﬂammatory cells and the
production of pro-ﬁbrogenic factors such as TGF-b1,
PDGF, PAI-1, and TIMP-1, thereby leading to renal allo-
graft interstitial ﬁbrosis and tubular atrophy.
Our present work has assessed the functional role of
chemokines, RANTES, and MCP-1, which play key roles in
the process of CRAD, and therefore suggest the potential
efﬁcacy of therapies targeting RANTES and MCP-1 or their
receptors in inhibiting inﬂammatory response and thus
treating CRAD.
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